88
Structure Therapeutics, a clinical-stage biopharmaceutical company backed by venture capital investors, including Sequoia Capital China, has filed to raise $100 million in an initial public offering (IPO) in the US.
The drug maker, headquartered in California with R&D operations in China, is looking to list its American Depositary Shares (ADS) on Nasdaq under the symbol GPCR, according to its heavily-redacted filing.
